SlideShare a Scribd company logo
1 of 7
What percentage of newly 
diagnosed breast cancer are 
stage 4? 
A.<10% 
B.10-30% 
C.30-50% 
D.50-80% 
E.Greater than 80%
What percentage of newly 
diagnosed breast cancer are 
stage 1? 
A.<10% 
B.10-30% 
C.30-50% 
D.50-80% 
E.Greater than 80%
What percentage of newly 
diagnosed breast cancer are 
stage 3? 
A.<10% 
B.10-30% 
C.30-50% 
D.50-80% 
E.Greater than 80%
What percentage of newly 
diagnosed breast cancer are 
hormone receptor positive? 
A.<10% 
B.10-30% 
C.30-50% 
D.50-80% 
E.Greater than 80%
What percentage of newly 
diagnosed breast cancer are 
Her -2 Neu positive? 
A.<10% 
B.10-30% 
C.30-50% 
D.50-80% 
E.Greater than 80%
Your choice of hormone therapy 
in adjuvant setting 
• Initial AI for 5 year 
• Initial AI for 10 year 
• 5 year AI then 5 years TAM 
• 5 year TAM and then 5 year of AI 
• 10 year TAM 
• 5 year TAM 
• Other
In stage 2/3 Her-2/neu positive breast 
cancer what is your choice of 
neoadjuvant therapy? 
• AC x4 then paclitaxel x 4 
• AC x4 then paclitaxel x 4+ trastuzumab+ 
pertuzumab 
• AC x4 then paclitaxel x 4 + trastuzumab 
• AC x4 then paclitaxel x 4 + pertuzumab

More Related Content

Viewers also liked

Sherriff oyster-industry-snap shot-1011-industry-edition
Sherriff oyster-industry-snap shot-1011-industry-editionSherriff oyster-industry-snap shot-1011-industry-edition
Sherriff oyster-industry-snap shot-1011-industry-editionprogressive01
 
Kertas kerja pencegahan dadah
Kertas kerja pencegahan dadahKertas kerja pencegahan dadah
Kertas kerja pencegahan dadahmurni mohamat
 
Ivailo dimitrov-2014.eng
Ivailo dimitrov-2014.engIvailo dimitrov-2014.eng
Ivailo dimitrov-2014.engSim Aleksiev
 
2008 to Now (Innovation)
2008 to Now (Innovation)2008 to Now (Innovation)
2008 to Now (Innovation)Yvonne Leong
 
40 ans de cinéma us 2016
40 ans de cinéma us 201640 ans de cinéma us 2016
40 ans de cinéma us 2016Guy Ros Agency
 
คำราชาศัพท์
คำราชาศัพท์คำราชาศัพท์
คำราชาศัพท์Marr Ps
 
Miley Cyrus Star Profile
Miley Cyrus Star ProfileMiley Cyrus Star Profile
Miley Cyrus Star ProfileJbraddy
 
My Presentation at Asha 22 Conference
My Presentation at Asha 22 Conference My Presentation at Asha 22 Conference
My Presentation at Asha 22 Conference Harsha
 
Elisaveta angelova-2015-1
Elisaveta angelova-2015-1Elisaveta angelova-2015-1
Elisaveta angelova-2015-1Sim Aleksiev
 
Money & Velocity
Money & VelocityMoney & Velocity
Money & VelocityFinTrust
 
Long term survival outcomes of Acute Promyelocytic Leukemia.
Long term survival outcomes of Acute Promyelocytic Leukemia. Long term survival outcomes of Acute Promyelocytic Leukemia.
Long term survival outcomes of Acute Promyelocytic Leukemia. spa718
 
Presentation 1 cond.
Presentation 1 cond.Presentation 1 cond.
Presentation 1 cond.lzanel
 
Benefits of good comunication
Benefits of good comunicationBenefits of good comunication
Benefits of good comunicationmparker94
 
9 stephen mulligan
9 stephen mulligan9 stephen mulligan
9 stephen mulliganspa718
 

Viewers also liked (20)

Sherriff oyster-industry-snap shot-1011-industry-edition
Sherriff oyster-industry-snap shot-1011-industry-editionSherriff oyster-industry-snap shot-1011-industry-edition
Sherriff oyster-industry-snap shot-1011-industry-edition
 
Kertas kerja pencegahan dadah
Kertas kerja pencegahan dadahKertas kerja pencegahan dadah
Kertas kerja pencegahan dadah
 
Ivailo dimitrov-2014.eng
Ivailo dimitrov-2014.engIvailo dimitrov-2014.eng
Ivailo dimitrov-2014.eng
 
Foire Auxerre 2016
 Foire Auxerre 2016 Foire Auxerre 2016
Foire Auxerre 2016
 
2008 to Now (Innovation)
2008 to Now (Innovation)2008 to Now (Innovation)
2008 to Now (Innovation)
 
Portaria 260-2014-ingles
Portaria 260-2014-inglesPortaria 260-2014-ingles
Portaria 260-2014-ingles
 
40 ans de cinéma us 2016
40 ans de cinéma us 201640 ans de cinéma us 2016
40 ans de cinéma us 2016
 
Dibenhooooooooooooooooooooooooooooooo
DibenhoooooooooooooooooooooooooooooooDibenhooooooooooooooooooooooooooooooo
Dibenhooooooooooooooooooooooooooooooo
 
คำราชาศัพท์
คำราชาศัพท์คำราชาศัพท์
คำราชาศัพท์
 
Miley Cyrus Star Profile
Miley Cyrus Star ProfileMiley Cyrus Star Profile
Miley Cyrus Star Profile
 
My Presentation at Asha 22 Conference
My Presentation at Asha 22 Conference My Presentation at Asha 22 Conference
My Presentation at Asha 22 Conference
 
Brand analytics for clients for site
Brand analytics for clients for siteBrand analytics for clients for site
Brand analytics for clients for site
 
Elisaveta angelova-2015-1
Elisaveta angelova-2015-1Elisaveta angelova-2015-1
Elisaveta angelova-2015-1
 
Money & Velocity
Money & VelocityMoney & Velocity
Money & Velocity
 
Long term survival outcomes of Acute Promyelocytic Leukemia.
Long term survival outcomes of Acute Promyelocytic Leukemia. Long term survival outcomes of Acute Promyelocytic Leukemia.
Long term survival outcomes of Acute Promyelocytic Leukemia.
 
Presentation 1 cond.
Presentation 1 cond.Presentation 1 cond.
Presentation 1 cond.
 
Takkonstruksjoner
TakkonstruksjonerTakkonstruksjoner
Takkonstruksjoner
 
Apex Athena P
Apex Athena PApex Athena P
Apex Athena P
 
Benefits of good comunication
Benefits of good comunicationBenefits of good comunication
Benefits of good comunication
 
9 stephen mulligan
9 stephen mulligan9 stephen mulligan
9 stephen mulligan
 

Similar to Ars breast cancer update

Deciding on treatment for prostate cancer 2018
Deciding on treatment for prostate cancer 2018Deciding on treatment for prostate cancer 2018
Deciding on treatment for prostate cancer 2018Robert J Miller MD
 
How to diagnose prostate cancer better in 2017 - IDF presentation
How to diagnose prostate cancer better in 2017 - IDF presentationHow to diagnose prostate cancer better in 2017 - IDF presentation
How to diagnose prostate cancer better in 2017 - IDF presentationMarc Laniado
 
1. dr r saha breast cancer screening npcdcs_dept. of community med
1. dr r saha  breast cancer screening npcdcs_dept. of community med1. dr r saha  breast cancer screening npcdcs_dept. of community med
1. dr r saha breast cancer screening npcdcs_dept. of community meddrdduttaM
 
Screening and prostate cancer
Screening and prostate cancerScreening and prostate cancer
Screening and prostate cancerDr Ankur Shah
 
USToo: About Prostate Cancer
USToo: About Prostate CancerUSToo: About Prostate Cancer
USToo: About Prostate CancerPCAinAZ
 
Epidemiology of breast cancer 2014 ap
Epidemiology of breast cancer 2014 apEpidemiology of breast cancer 2014 ap
Epidemiology of breast cancer 2014 apletymbou
 
POC Breast 1 | 2007 - Adjuvant Endocrine Therapy
POC Breast 1 | 2007 -  	Adjuvant Endocrine TherapyPOC Breast 1 | 2007 -  	Adjuvant Endocrine Therapy
POC Breast 1 | 2007 - Adjuvant Endocrine Therapyrtp
 
POC Breast 1 | 2007 - Adjuvant Trastuzumab
POC Breast 1 | 2007 - Adjuvant TrastuzumabPOC Breast 1 | 2007 - Adjuvant Trastuzumab
POC Breast 1 | 2007 - Adjuvant Trastuzumabrtp
 
PSA test accuracy
PSA test accuracyPSA test accuracy
PSA test accuracyGaetan Lion
 
Hrtandgenitalcancer
HrtandgenitalcancerHrtandgenitalcancer
Hrtandgenitalcancerjhardesty
 

Similar to Ars breast cancer update (20)

Breast Cancer Screening Presentation - PiPP
Breast Cancer Screening Presentation - PiPPBreast Cancer Screening Presentation - PiPP
Breast Cancer Screening Presentation - PiPP
 
Deciding on treatment for prostate cancer 2018
Deciding on treatment for prostate cancer 2018Deciding on treatment for prostate cancer 2018
Deciding on treatment for prostate cancer 2018
 
How to diagnose prostate cancer better in 2017 - IDF presentation
How to diagnose prostate cancer better in 2017 - IDF presentationHow to diagnose prostate cancer better in 2017 - IDF presentation
How to diagnose prostate cancer better in 2017 - IDF presentation
 
Us2aware
Us2awareUs2aware
Us2aware
 
1. dr r saha breast cancer screening npcdcs_dept. of community med
1. dr r saha  breast cancer screening npcdcs_dept. of community med1. dr r saha  breast cancer screening npcdcs_dept. of community med
1. dr r saha breast cancer screening npcdcs_dept. of community med
 
Prof Richard Peto on Breast Cancer Screening
Prof Richard Peto on Breast Cancer ScreeningProf Richard Peto on Breast Cancer Screening
Prof Richard Peto on Breast Cancer Screening
 
pca screening.pdf
pca screening.pdfpca screening.pdf
pca screening.pdf
 
Prostate health
Prostate healthProstate health
Prostate health
 
ABC1 - P. Francis - Elderly patients
ABC1 - P. Francis - Elderly patientsABC1 - P. Francis - Elderly patients
ABC1 - P. Francis - Elderly patients
 
Postmenapausal bleding
Postmenapausal bledingPostmenapausal bleding
Postmenapausal bleding
 
Cancer screening for seniors
Cancer screening for seniorsCancer screening for seniors
Cancer screening for seniors
 
Screening and prostate cancer
Screening and prostate cancerScreening and prostate cancer
Screening and prostate cancer
 
USToo: About Prostate Cancer
USToo: About Prostate CancerUSToo: About Prostate Cancer
USToo: About Prostate Cancer
 
Epidemiology of breast cancer 2014 ap
Epidemiology of breast cancer 2014 apEpidemiology of breast cancer 2014 ap
Epidemiology of breast cancer 2014 ap
 
POC Breast 1 | 2007 - Adjuvant Endocrine Therapy
POC Breast 1 | 2007 -  	Adjuvant Endocrine TherapyPOC Breast 1 | 2007 -  	Adjuvant Endocrine Therapy
POC Breast 1 | 2007 - Adjuvant Endocrine Therapy
 
POC Breast 1 | 2007 - Adjuvant Trastuzumab
POC Breast 1 | 2007 - Adjuvant TrastuzumabPOC Breast 1 | 2007 - Adjuvant Trastuzumab
POC Breast 1 | 2007 - Adjuvant Trastuzumab
 
CCSN EUPROMS.pptx
CCSN EUPROMS.pptxCCSN EUPROMS.pptx
CCSN EUPROMS.pptx
 
PSA test accuracy
PSA test accuracyPSA test accuracy
PSA test accuracy
 
Hrtandgenitalcancer
HrtandgenitalcancerHrtandgenitalcancer
Hrtandgenitalcancer
 
Prostate video 1
Prostate video 1Prostate video 1
Prostate video 1
 

More from spa718

1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotai1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotaispa718
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery spa718
 
Controversies in Colorectal Cancer
Controversies in Colorectal CancerControversies in Colorectal Cancer
Controversies in Colorectal Cancerspa718
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancerspa718
 
Chemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerChemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerspa718
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinomaspa718
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancerspa718
 
Surgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung CancerSurgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung Cancerspa718
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancerspa718
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancerspa718
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancerspa718
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancerspa718
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancerspa718
 
Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015spa718
 
Updates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast CancerUpdates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast Cancerspa718
 
Regulatory T Cells and GVHD
Regulatory T Cells and GVHDRegulatory T Cells and GVHD
Regulatory T Cells and GVHDspa718
 
Immunotherapy for Multiple Myeloma
Immunotherapy for Multiple MyelomaImmunotherapy for Multiple Myeloma
Immunotherapy for Multiple Myelomaspa718
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapyspa718
 
AML and Cell Therapy
AML and Cell TherapyAML and Cell Therapy
AML and Cell Therapyspa718
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Updatespa718
 

More from spa718 (20)

1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotai1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotai
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery
 
Controversies in Colorectal Cancer
Controversies in Colorectal CancerControversies in Colorectal Cancer
Controversies in Colorectal Cancer
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancer
 
Chemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerChemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancer
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinoma
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancer
 
Surgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung CancerSurgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung Cancer
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancer
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancer
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancer
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancer
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancer
 
Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015
 
Updates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast CancerUpdates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast Cancer
 
Regulatory T Cells and GVHD
Regulatory T Cells and GVHDRegulatory T Cells and GVHD
Regulatory T Cells and GVHD
 
Immunotherapy for Multiple Myeloma
Immunotherapy for Multiple MyelomaImmunotherapy for Multiple Myeloma
Immunotherapy for Multiple Myeloma
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapy
 
AML and Cell Therapy
AML and Cell TherapyAML and Cell Therapy
AML and Cell Therapy
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Update
 

Ars breast cancer update

  • 1. What percentage of newly diagnosed breast cancer are stage 4? A.<10% B.10-30% C.30-50% D.50-80% E.Greater than 80%
  • 2. What percentage of newly diagnosed breast cancer are stage 1? A.<10% B.10-30% C.30-50% D.50-80% E.Greater than 80%
  • 3. What percentage of newly diagnosed breast cancer are stage 3? A.<10% B.10-30% C.30-50% D.50-80% E.Greater than 80%
  • 4. What percentage of newly diagnosed breast cancer are hormone receptor positive? A.<10% B.10-30% C.30-50% D.50-80% E.Greater than 80%
  • 5. What percentage of newly diagnosed breast cancer are Her -2 Neu positive? A.<10% B.10-30% C.30-50% D.50-80% E.Greater than 80%
  • 6. Your choice of hormone therapy in adjuvant setting • Initial AI for 5 year • Initial AI for 10 year • 5 year AI then 5 years TAM • 5 year TAM and then 5 year of AI • 10 year TAM • 5 year TAM • Other
  • 7. In stage 2/3 Her-2/neu positive breast cancer what is your choice of neoadjuvant therapy? • AC x4 then paclitaxel x 4 • AC x4 then paclitaxel x 4+ trastuzumab+ pertuzumab • AC x4 then paclitaxel x 4 + trastuzumab • AC x4 then paclitaxel x 4 + pertuzumab